U.S. Markets close in 4 hrs 30 mins
  • S&P 500

    4,128.20
    -11.86 (-0.29%)
     
  • Dow 30

    32,834.15
    +1.61 (+0.00%)
     
  • Nasdaq

    12,511.49
    -132.97 (-1.05%)
     
  • Russell 2000

    1,916.08
    -25.13 (-1.29%)
     
  • Crude Oil

    91.34
    +0.58 (+0.64%)
     
  • Gold

    1,809.30
    +4.10 (+0.23%)
     
  • Silver

    20.45
    -0.16 (-0.77%)
     
  • EUR/USD

    1.0225
    +0.0037 (+0.3681%)
     
  • 10-Yr Bond

    2.7900
    +0.0250 (+0.90%)
     
  • Vix

    21.87
    +0.58 (+2.72%)
     
  • GBP/USD

    1.2087
    +0.0016 (+0.1342%)
     
  • USD/JPY

    134.9530
    -0.0170 (-0.0126%)
     
  • BTC-USD

    23,140.28
    -928.18 (-3.86%)
     
  • CMC Crypto 200

    537.05
    -20.30 (-3.64%)
     
  • FTSE 100

    7,494.79
    +12.42 (+0.17%)
     
  • Nikkei 225

    27,999.96
    -175.94 (-0.62%)
     

GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) --  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close.

Management will host a conference call on Monday, August 8, 2022, at 4:30 p.m. ET to discuss second quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT’s website at www.gbt.com in the Investors section. The archived audio webcast will be available for one month following the event.

About Global Blood Therapeutics
Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650.410.3258
simmergut@gbt.com

Courtney Roberts (investors)
650.351.7881
croberts@gbt.com